Peter Dilaura

President and CEO
San Francisco, California, United States

Professional Overview

Peter Dilaura is an accomplished life sciences executive with over 25 years of experience driving innovation and strategic growth in the biotechnology and pharmaceutical industries. As the President and CEO of Initial Therapeutics, he is responsible for leading the company's mission to develop transformative therapies for patients. Additionally, Peter serves as a Strategic Advisor to Sonoma Biotherapeutics, where he provides strategic guidance to the executive team. He also serves on the Board of Directors at Character Biosciences, leveraging his deep industry expertise to contribute to the organization's long-term success.

Experience Summary

Current Roles

President and CEO, Initial Therapeutics (2024-04-01 to Present)

• Providing visionary leadership to guide Initial Therapeutics' strategic direction and oversee the development and commercialization of its innovative therapeutic pipeline

• Strengthening the company's research and development capabilities to accelerate the advancement of novel drug candidates

• Fostering collaborative partnerships with key industry players to expand the company's reach and impact

Strategic Advisor, Sonoma Biotherapeutics (2024-04-01 to Present)

• Offering strategic guidance and counsel to the executive team to support Sonoma Biotherapeutics' growth and expansion initiatives

• Leveraging his extensive industry expertise to help the company navigate complex regulatory and market dynamics

Board of Directors, Character Biosciences (2020-01-01 to Present)

• Serving on the Board of Directors, contributing to the company's long-term strategic planning and decision-making processes

• Providing oversight and guidance to ensure Character Biosciences' alignment with industry best practices and regulatory requirements

Career Progression

Prior to his current roles, Peter held several senior leadership positions in the biotechnology and pharmaceutical industries. He served as the Chief Business and Strategy Officer at Sonoma Biotherapeutics, where he was responsible for driving the company's strategic initiatives and business development activities.

Before that, Peter was an Entrepreneur in Residence at Third Rock Ventures, where he leveraged his expertise to advise and support the firm's portfolio companies. He also served as a Strategic Advisor to the Dementia Discovery Fund, contributing his industry knowledge and insights to the organization's efforts to develop innovative treatments for neurodegenerative diseases.

Peter's earlier career includes roles as the President and CEO of Second Genome, Inc., where he led the company's successful clinical development and commercialization efforts. He also held senior positions at Ingenuity Systems and Ventro/Chemdex, where he played a key role in driving business growth and strategic partnerships.

Academic Background

Peter holds a Bachelor of Science degree in Biology from the University of California, San Diego, where he graduated with honors.

Areas of Expertise

• Strategic leadership and executive management in the biotechnology and pharmaceutical industries

• Research and development of innovative therapeutic solutions

• Business development, strategic partnerships, and commercialization

• Regulatory compliance and navigating complex industry dynamics

• Entrepreneurship and venture capital advisory

Professional Impact

Throughout his career, Peter has demonstrated a strong track record of driving innovation, fostering collaborative partnerships, and delivering tangible results for the organizations he has served. His strategic vision, industry expertise, and ability to inspire high-performing teams have been instrumental in his success.

Under Peter's leadership, Second Genome achieved significant milestones, including the successful completion of multiple clinical trials and the establishment of key partnerships with leading industry players. His contributions have been recognized by his peers, and he is a respected voice in the biotechnology and pharmaceutical communities.

Conclusion

With his extensive experience, deep industry knowledge, and proven leadership abilities, Peter Dilaura is well-positioned to continue driving the success of Initial Therapeutics and contributing to the advancement of transformative therapies that improve patient outcomes. His strategic vision, collaborative approach, and commitment to innovation make him a valuable asset to the organizations he serves.